Table 3 Meta-analysis of the relationship between the expression of LOXL2 and clinicopathological characters.
Categories (n) | Researches | Model | I2 (%) | OR (95% CI) |
|---|---|---|---|---|
Age | 22 | Random-effects | 43.6 | 1.33(1.06–1.66) |
Gender | 25 | Fixed-effects | 2.7 | 1.07(0.92–1.24) |
T stage | 15 | Random-effects | 73.0 | 2.02(1.33–3.07) |
LNM | 22 | Random-effects | 83.6 | 1.71(1.11–2.64) |
TNM stage | 18 | Random-effects | 63.0 | 1.83(1.28–2.62) |
Differentiation | 13 | Fixed-effects | 34.6 | 1.33(0.99–1.79) |
Tumor size | 13 | Random-effects | 42.8 | 1.53(1.13–2.08) |
Distant metastasis | 10 | Fixed-effects | 37.9 | 2.63(1.98–3.49) |
Pathological grade | 10 | Random-effects | 59.7 | 1.38(0.88–2.16) |
Lymphovascular involvement | 7 | Random-effects | 75.9 | 2.62(1.11–6.19) |
Portal vein invasion | 5 | Random-effects | 57.6 | 3.19(1.60–6.36) |
Perineural invasion | 4 | Fixed-effects | 7.0 | 1.24(0.70–2.19) |
